Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Gender, cytidine deaminase, and 5-aza/decitabine--letter.

Ciccolini J, Peters GJ, Giovannetti E.

Clin Cancer Res. 2013 Jun 1;19(11):3105. doi: 10.1158/1078-0432.CCR-13-0483. Epub 2013 May 8. No abstract available.

2.

Gender, cytidine deaminase, and 5-aza/decitabine--response.

Mahfouz RZ, Koh LS, Teo M, Chee CL, Toh HC, Saunthararajah Y.

Clin Cancer Res. 2013 Jun 1;19(11):3106-7. doi: 10.1158/1078-0432.CCR-13-0872. Epub 2013 May 8. No abstract available.

3.

Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.

Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A, Terse P, Covey J, Chan K, Ling Y, Engelke KJ, Sekeres MA, Tiu R, Maciejewski J, Radivoyevitch T, Saunthararajah Y.

Clin Cancer Res. 2013 Feb 15;19(4):938-48. doi: 10.1158/1078-0432.CCR-12-1722. Epub 2013 Jan 3.

4.

Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?

Lowder JN, Taverna P, Issa JP.

Epigenomics. 2015 Oct;7(7):1083-8. doi: 10.2217/epi.15.66. Epub 2015 Nov 6. No abstract available.

PMID:
26541345
5.

Clinical development of demethylating agents in hematology.

Navada SC, Steinmann J, Lübbert M, Silverman LR.

J Clin Invest. 2014 Jan;124(1):40-6. doi: 10.1172/JCI69739. Epub 2014 Jan 2. Review.

6.

Chemoprotection of murine hematopoietic cells by combined gene transfer of cytidine deaminase (CDD) and multidrug resistance 1 gene (MDR1).

Brennig S, Lachmann N, Buchegger T, Hetzel M, Schambach A, Moritz T.

J Exp Clin Cancer Res. 2015 Dec 12;34:148. doi: 10.1186/s13046-015-0260-4.

7.

[5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].

Gao S, Hu XH, Qiu HY, Xu Y, Jin ZM, He GS, Tang XW, Han Y, Chen SN, Sun AN, Wu DP.

Zhonghua Xue Ye Xue Za Zhi. 2013 Jun;34(6):542-3. doi: 10.3760/cma.j.issn.0253-2727.2013.06.019. Chinese. No abstract available.

PMID:
23827117
8.

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.

Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, Blum W, Marcucci G.

Leukemia. 2012 May;26(5):1106-7. doi: 10.1038/leu.2011.342. Epub 2011 Nov 29. No abstract available.

9.
10.

Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.

Yun H, Damm F, Yap D, Schwarzer A, Chaturvedi A, Jyotsana N, Lübbert M, Bullinger L, Döhner K, Geffers R, Aparicio S, Humphries RK, Ganser A, Heuser M.

Haematologica. 2014 Sep;99(9):1456-64. doi: 10.3324/haematol.2013.101386. Epub 2014 Jun 3.

11.

Genomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia.

Hyrenius-Wittsten A, Sturesson H, Bidgoli M, Jonson T, Ehinger M, Lilljebjörn H, Scheding S, Andersson AK.

Genes Chromosomes Cancer. 2016 Nov;55(11):847-54. doi: 10.1002/gcc.22384. Epub 2016 Jul 4.

PMID:
27240832
12.

Pharmacokinetic evaluation of decitabine for the treatment of leukemia.

Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E.

Expert Opin Drug Metab Toxicol. 2011 May;7(5):661-72. doi: 10.1517/17425255.2011.575062. Review.

PMID:
21500965
13.

Rare occurrence of DNMT3A mutations in myelodysplastic syndromes.

Thol F, Winschel C, Lüdeking A, Yun H, Friesen I, Damm F, Wagner K, Krauter J, Heuser M, Ganser A.

Haematologica. 2011 Dec;96(12):1870-3. doi: 10.3324/haematol.2011.045559. Epub 2011 Aug 31.

14.

Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.

Fanciullino R, Mercier C, Serdjebi C, Berda Y, Fina F, Ouafik L, Lacarelle B, Ciccolini J, Costello R.

Pharmacogenet Genomics. 2015 Jun;25(6):317-21. doi: 10.1097/FPC.0000000000000139.

PMID:
25850965
15.

[Genome-wide analysis of AML and MDS].

Ogawa S.

Nihon Rinsho. 2012 Apr;70 Suppl 2:113-8. Japanese. No abstract available.

PMID:
23133938
16.

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ.

N Engl J Med. 2016 Nov 24;375(21):2023-2036. doi: 10.1056/NEJMoa1605949.

17.

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.

Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H.

Lancet Oncol. 2015 Sep;16(9):1099-1110. doi: 10.1016/S1470-2045(15)00038-8. Epub 2015 Aug 19.

18.

Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.

Gao S, Li Z, Fu JH, Hu XH, Xu Y, Jin ZM, Tang XW, Han Y, Chen SN, Sun AN, Wu DP, Qiu HY.

Asian Pac J Cancer Prev. 2015;16(15):6627-32.

19.

Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.

Duong VH, Bhatnagar B, Zandberg DP, Vannorsdall EJ, Tidwell ML, Chen Q, Baer MR.

Leuk Lymphoma. 2015 Jun;56(6):1718-22. doi: 10.3109/10428194.2014.966708. Epub 2014 Nov 3.

PMID:
25263320
20.

Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.

Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, Vij R, Abboud CN, Stockerl-Goldstein KE, Jacoby MA, Uy GL, Westervelt P, DiPersio JF.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1761-9. doi: 10.1016/j.bbmt.2015.05.026. Epub 2015 Jun 5.

Supplemental Content

Support Center